Floatz logo

Regorafenib

Iparomlimab and Tuvonralimab Injection

JIANG LONGWEISmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Iparomlimab and Tuvonralimab Injection cohort.

Asset / SponsorPhaseRating
Tuvonralimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2B
Iparomlimab
Tianjin Medical University Cancer Institute and Hospital
Phase 2B
Irinotecan
Nanfang Hospital, Southern Medical University
Phase 2CCC
(+)-VINCRISTINE
Nanfang Hospital, Southern Medical University
Phase 2CCC

Same molecule, other indications

Regorafenib is also rated in:

gastrointestinal stromal tumorDormant
BBB
Indicative ·
73 / 100
View asset →
colorectal neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
RegorafenibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →